ArticleMolecular cell2019
Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay.
Open access · greenAbstract read
In one paragraph
Article in Molecular cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 87 citations in OpenAlex.
- iMPI: An Integrative Database for MicroProteins Encoded by Intron Retention in Tumors.Proteomics · 2026Article
- Potyviruses recruit host eIF4A3 to block m6A-mediated RNA decay by steric hindrance of viral RNA methylation in plants.Nucleic acids research · 2026Article
- Snord67 promotes breast cancer metastasis by guiding U6 modification and modulating the splicing landscape.Nature communications · 2025Article
- RNA splicing: Novel star in pulmonary diseases with a treatment perspective.Acta pharmaceutica Sinica. B · 2025Review
- TRIM8 inhibits porcine epidemic diarrhoea virus replication by targeting and ubiquitinately degrading the nucleocapsid protein.Veterinary research · 2025Article
- Divergent roles of mNature communications · 2025Article
- Integrated analysis of disulfidptosis-related genes SLC7A11, SLC3A2, RPN1 and NCKAP1 across cancers.Discover oncology · 2024Article
- Article
- A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation.Scientific reports · 2024Article
- Nuclear mRNA decay: regulatory networks that control gene expression.Nature reviews. Genetics · 2024Review
- Regulatory roles of N6-methyladenosine (mCancer gene therapy · 2024Review
- Systematic identification of post-transcriptional regulatory modules.Nature communications · 2024Article
- Decoding the specificity of mMolecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Synthesis and Regulation of miRNA, Its Role in Oncogenesis, and Its Association with Colorectal Cancer Progression, Diagnosis, and Prognosis.Diagnostics (Basel, Switzerland) · 2024Review
- The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target.BMC cancer · 2024Review
- The role of N6-methyladenosine modification in tumor angiogenesis.Frontiers in oncology · 2024Review
- ABCA3, a tumor suppressor gene, inhibits the proliferation, migration and invasion of lung adenocarcinoma by regulating the epithelial‑mesenchymal transition process.Oncology letters · 2023Article
- Changes in mHeliyon · 2023Article
- The roles and implications of RNA mNature reviews. Clinical oncology · 2023Review
- An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus.Nature cell biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Lisa FishDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Albertas NavickasDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Bruce CulbertsonDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Yichen XuDepartment of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Hoang C B NguyenLaboratory of Systems Cancer Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
Steven ZhangDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Myles HochmanDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Ross OkimotoHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
Brian D DillProteome Resource Center, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
Henrik MolinaProteome Resource Center, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
Hamed S NajafabadiDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; McGill University and Genome Quebec Innovation Centre, Montreal, QC H3A 0G1, Canada.
Claudio AlarcónDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
Davide RuggeroDepartment of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Hani GoodarziDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: hani.goodarzi@ucsf.edu.
University of California, San Francisco · USRockefeller University · USMcGill Genome Centre · CAYale Cancer Center · US
Funding
Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MThe role of deregulated protein synthesis control in Myc-induced tumorigenesisR01CA140456 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUGGERO, DAVIDE · 2009 to 2019
$3.3MPharmcogenomic dissection of mTOR translational targets in prostate cancerR01CA154916 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUGGERO, DAVIDE · 2011 to 2018
$2.8MTargeted regulation of transcript stability through RNA methylation and intron retentionR01GM123977 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOODARZI, HANI · 2017 to 2021
$2.0MTherapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasisK08CA222625 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKIMOTO, ROSS · 2018 to 2022
$887kSystematic dissection of an aberrant splicing program driving cancer metastasisR00CA194077 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOODARZI, HANI · 2016 to 2018
$746kNCI NIH HHS K08 CA222625NCI NIH HHS R00 CA194077NCI NIH HHS R01 CA140456NCI NIH HHS R01 CA154916NCI NIH HHS T32 CA108462NIGMS NIH HHS R01 GM123977
Abstract
Post-transcriptional regulation of RNA stability is a key step in gene expression control. We describe a regulatory program, mediated by the RNA binding protein TARBP2, that controls RNA stability in the nucleus. TARBP2 binding to pre-mRNAs results in increased intron retention, subsequently leading to targeted degradation of TARBP2-bound transcripts. This is mediated by TARBP2 recruitment of the m
Indexed as
RNA SplicingRNA StabilityAnimalsATP-Binding Cassette TransportersCell Cycle ProteinsCell Line, TumorForkhead Transcription FactorsHumansLung NeoplasmsMiceMice, Inbred NODMice, SCIDNeoplasm ProteinsRNA-Binding ProteinsRNA, NeoplasmTrans-Activation Responsive RNA-Binding ProteinABCA3 protein, humanATP-Binding Cassette TransportersCell Cycle ProteinsForkhead Transcription FactorsFOXN3 protein, humanNeoplasm ProteinsRNA-Binding ProteinsRNA, NeoplasmTrans-Activation Responsive RNA-Binding ProteinTrans-ActivatorsZNF143 protein, humanbreast cancerintron retentionlung cancerm(6)Ametastasisnuclear RNA decaypost-transcriptional regulationsplicing regulationTARBP2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.